Related Experiment Video
Updated: Jul 21, 2026

05:12
Intravital Microscopy of Leukocyte-endothelial and Platelet-leukocyte Interactions in Mesenterial Veins in Mice
Published on: August 13, 2015
Intravascular platelet aggregation and acute respiratory insufficiency
Summary
Intravascular platelet aggregation causes acute respiratory distress and hypoxemia in cats. These effects are reversible, suggesting microembolization leads to temporary pulmonary insufficiency.
Area of Science:
- Cardiovascular Physiology
- Respiratory Physiology
- Hematology
Background:
- Intravascular platelet aggregation is implicated in various thromboembolic events.
- The specific respiratory consequences of platelet aggregation are not fully elucidated.
- Understanding these effects is crucial for managing respiratory complications.
Purpose of the Study:
- To investigate the respiratory effects of induced intravascular platelet aggregation in a feline model.
- To determine the reversibility of these respiratory changes.
- To explore potential mechanisms underlying the observed respiratory distress.
Main Methods:
- Platelet aggregation was induced via collagen fibril infusion in anesthetized cats.
- Animals were studied under mechanical ventilation or spontaneous breathing.
- Respiratory parameters, including arterial blood gases and airway pressures, were monitored.
Main Results:
- Collagen infusion led to acute respiratory distress, severe arterial hypoxemia, and tachypnea in both ventilation groups.
- Airway and pulmonary vascular constriction were observed.
- Most physiological changes reversed within 2 hours post-infusion; deep lung inflations improved function.
Conclusions:
- Intravascular platelet aggregation can cause acute, reversible pulmonary insufficiency due to microembolization.
- Arterial hypoxemia likely results from ventilation-perfusion ratio disturbances secondary to airway changes.
- Additional factors beyond platelet aggregation may be required for irreversible respiratory insufficiency.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Acute Respiratory Failure-I
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Acute Respiratory Failure-II
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-III
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without causing...
Acute Respiratory Failure-V
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...

